Holen Sie sich die Stockscreener-App
31.17
2.43%
-0.7661
Schlusskurs vom Vortag:
$31.94
Offen:
$31.34
24-Stunden-Volumen:
701.26K
Relative Volume:
0.34
Marktkapitalisierung:
$19.20B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
20.78
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
-1.72%
1M Leistung:
+8.74%
6M Leistung:
+40.07%
1J Leistung:
+40.95%
1-Tages-Spanne:
$31.14
$31.58
1-Wochen-Bereich:
$31.14
$32.41
52-Wochen-Spanne:
$17.23
$33.65
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
31.17 | 19.67B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.64 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.30 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.67 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.16 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.58 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - GlobeNewswire Inc.
Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World
AI Plays Lead Five Stocks To Watch Near Buy Points - Investor's Business Daily
Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB - Defense World
JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter - Investor's Business Daily
Genmab A/S Sponsored ADR $GMAB Position Reduced by Russell Investments Group Ltd. - MarketBeat
Capital Fund Management S.A. Has $4.68 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arbor Realty Trust Inc (ABR): What is the Risk Factor? - fostersleader.com
Level Four Advisory Services LLC Acquires 12,888 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Rockefeller Capital Management L.P. Purchases New Shares in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning - Defense World
AlphaCore Capital LLC Invests $44,000 in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
AIMZ Investment Advisors LLC Has $3.43 Million Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Vera Therapeutics Stock Earns RS Rating Upgrade - Investor's Business Daily
Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright - Defense World
Ocular Therapeutix Stock Earns 81 RS Rating - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright - Defense World
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade - Investor's Business Daily
Leerink Partnrs Forecasts Weaker Earnings for Genmab A/S - Defense World
Stocks With Rising Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by William Blair - Defense World
Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd - Defense World
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - MSN
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Ingalls & Snyder LLC - MarketBeat
William Blair Predicts Genmab A/S FY2027 Earnings - Defense World
Short Interest in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Increases By 59.3% - MarketBeat
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Vanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World
Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World
Truist Financial Corp Reduces Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):